Table 2 Stratified analysis of pooled hazard ratios for penile cancer patients with ENE
From: The importance of extranodal extension in penile cancer: a meta-analysis
Analysis | No. of studies (No. of patients) | HR/OR (95 % CI) | P Value | Model | Heterogeneity | |
|---|---|---|---|---|---|---|
I2 (%) | Phet | |||||
Whole group CSS | 4(581) | 1.90(1.35,2.67) | 0.0002 | Fixed | 29 | 0.24 |
Subgroup1: | ||||||
Location | ||||||
European | 2(381) | 1.54 (1.01, 2.36) | 0.05 | Fixed | 0 % | 0.40 |
North American | 2(200) | 2.79 (1.58, 4.92) | 0.0004 | Fixed | 0 % | 0.36 |
Subgroup2: | ||||||
Follow-up time | ||||||
< 36 months | 2(126) | 1.37 (0.68, 2.76) | 0.38 | Fixed | 0 % | 0.45 |
≥ 36 months | 2(455) | 2.26 (1.18, 4.34) | 0.01 | Random | 60 % | 0.11 |
Whole group PLNM | 4(353) | 4.95 (2.58, 9.49) | <0.00001 | Fixed | 0 | 0.51 |
Subgroup1: | ||||||
Sample size | ||||||
≥ 100 | 2(244) | 5.54 (2.63, 11.68) | <0.00001 | Fixed | 0 % | 0.44 |
< 100 | 2(109) | 3.43(0.90, 13.11) | 0.07 | Fixed | 26 % | 0.25 |
Subgroup2: | ||||||
Identification of study object | ||||||
Individual patient | 2(178) | 2.82 (0.99, 7.98) | 0.05 | Fixed | 0 % | 0.71 |
Groin basin | 2(221) | 7.11 (3.08, 16.38) | <0.00001 | Fixed | 0 % | 0.56 |